Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cel...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Default Article |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/2134/37113 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
rr-article-9567734 |
---|---|
record_format |
Figshare |
spelling |
rr-article-95677342019-02-13T00:00:00Z Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods Richard Harrison (2572996) Ezequiel Zylberberg (7214168) Simon Ellison (7214171) Bruce L. Levine (7214174) Mechanical engineering not elsewhere classified Cell therapy Chimeric antigen receptor Chimeric antigen receptor–T cells Manufacturing Offshoring Production management Logistics Supply chain Mechanical Engineering not elsewhere classified Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic model could significantly reduce aggregate cost of goods (COGs), potentially improving market penetration of these life-saving treatments. Furthermore, the shift toward offshore production may help reduce manufacturing costs. In this article, we examine production costs of an allogeneic CAR-T cell process and the potential differential manufacturing costs between regions. Two offshore locations are compared with regions within the United States. The critical findings of this article identify the COGs challenges facing manufacturing of allogeneic CAR-T immunotherapies, how these may evolve as production is sent offshore and the wider implication this trend could have. 2019-02-13T00:00:00Z Text Journal contribution 2134/37113 https://figshare.com/articles/journal_contribution/Chimeric_antigen_receptor_T_cell_therapy_manufacturing_modelling_the_effect_of_offshore_production_on_aggregate_cost_of_goods/9567734 CC BY 4.0 |
institution |
Loughborough University |
collection |
Figshare |
topic |
Mechanical engineering not elsewhere classified Cell therapy Chimeric antigen receptor Chimeric antigen receptor–T cells Manufacturing Offshoring Production management Logistics Supply chain Mechanical Engineering not elsewhere classified |
spellingShingle |
Mechanical engineering not elsewhere classified Cell therapy Chimeric antigen receptor Chimeric antigen receptor–T cells Manufacturing Offshoring Production management Logistics Supply chain Mechanical Engineering not elsewhere classified Richard Harrison Ezequiel Zylberberg Simon Ellison Bruce L. Levine Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods |
description |
Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic model could significantly reduce aggregate cost of goods (COGs), potentially improving market penetration of these life-saving treatments. Furthermore, the shift toward offshore production may help reduce manufacturing costs. In this article, we examine production costs of an allogeneic CAR-T cell process and the potential differential manufacturing costs between regions. Two offshore locations are compared with regions within the United States. The critical findings of this article identify the COGs challenges facing manufacturing of allogeneic CAR-T immunotherapies, how these may evolve as production is sent offshore and the wider implication this trend could have. |
format |
Default Article |
author |
Richard Harrison Ezequiel Zylberberg Simon Ellison Bruce L. Levine |
author_facet |
Richard Harrison Ezequiel Zylberberg Simon Ellison Bruce L. Levine |
author_sort |
Richard Harrison (2572996) |
title |
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods |
title_short |
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods |
title_full |
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods |
title_fullStr |
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods |
title_full_unstemmed |
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods |
title_sort |
chimeric antigen receptor–t cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods |
publishDate |
2019 |
url |
https://hdl.handle.net/2134/37113 |
_version_ |
1797098460920414208 |